Gimatecan
Sponsors
Jonsson Comprehensive Cancer Center, Novartis Pharmaceuticals, Novartis, M.D. Anderson Cancer Center, Lee's Pharmaceutical Limited
Conditions
Advanced Solid TumorsBrain and Central Nervous System TumorsEpithelial Ovarian CancerFallopian Tube CancerMDSMyelodysplastic SyndromesPancreatic CancerPeritoneal Cancer
Phase 1
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
CompletedNCT00087061
Start: 2004-05-31End: 2005-06-30Updated: 2013-07-18
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
CompletedNCT00410358
Start: 2006-06-30Updated: 2020-12-19
Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors
CompletedNCT00420485
Start: 2006-03-31End: 2010-11-30Updated: 2013-04-19
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
CompletedNCT00441610
Start: 2007-01-31Updated: 2020-12-19
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
CompletedNCT00487058
Start: 2007-05-31Target: 28Updated: 2009-11-19
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes
CompletedNCT00493571
Start: 2007-08-31End: 2014-05-31Updated: 2015-05-13
Phase 2
A Study of Gimatecan (ST1481) in Small Cell Lung Cancer
NCT04501029
Start: 2020-10-01End: 2023-10-01Target: 70Updated: 2020-08-06
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
NCT04571489
Start: 2020-12-01End: 2023-12-01Target: 60Updated: 2020-10-01
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
NCT04846842
Start: 2021-07-01End: 2023-07-01Target: 46Updated: 2021-04-19